Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen: http://doi.org/10.25358/openscience-5969
Autoren: Krajnak, Slavomir
Schnatz, C.
Almstedt, Katrin
Brenner, Walburgis
Haertner, F.
Heimes, Anne-Sophie
Lebrecht, Antje
Makris, G.-M.
Schwab, Roxana
Hasenburg, Annette
Schmidt, Marcus
Battista, Marco J.
Titel: Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer : results of an exploratory case–control study
Online-Publikationsdatum: 4-Jun-2021
Erscheinungsdatum: 2020
Sprache des Dokuments: Englisch
Zusammenfassung/Abstract: PURPOSE There is growing interest in low-dose metronomic chemotherapy (LDMC) in metastatic breast cancer (MBC). In this retrospective case–control analysis, we compared the efficacy of LDMC and conventional chemotherapy (CCT) in MBC. METHODS Each LDMC patient receiving oral cyclophosphamide (CTX) (50 mg daily) and methotrexate (MTX) (2.5 mg every other day) was matched with two controls who received CCT. Age, number of chemotherapy lines and metastatic sites as well as hormone receptor (HR) status were considered as matching criteria. Primary endpoint was disease control rate longer than 24 weeks (DCR). Secondary endpoints were progression-free survival (PFS), duration of response (DoR) and subgroup analyses using the matching criteria. RESULTS 40 cases and 80 controls entered the study. 30.0% patients with LDMC and 22.5% patients with CCT showed DCR (p = 0.380). The median PFS was 12.0 weeks in both groups (p = 0.218) and the median DoR was 31.0 vs. 20.5 weeks (p = 0.383), respectively. Among younger patients, DCR was 40.0% in LDMC vs. 25.0% in the CCT group (p = 0.249). DCR was achieved in 33.3% vs. 26.2% non-heavily pretreated patients (p = 0.568) and in 36.0% vs. 18.0% patients without multiple metastases (p = 0.096), respectively. In the HR-positive group, 30.0% LDMC vs. 28.3% CCT patients showed DCR (p = 1.000). Among triple-negative patients, DCR was achieved in 30.0% LDMC and 5.0% CCT patients (p = 0.095). CONCLUSIONS We demonstrated a similar efficacy of LDMC compared to CCT in the treatment of MBC. Thus, LDMC may be a valuable treatment option in selected MBC patients.
DDC-Sachgruppe: 610 Medizin
610 Medical sciences
Veröffentlichende Institution: Johannes Gutenberg-Universität Mainz
Organisationseinheit: FB 04 Medizin
Veröffentlichungsort: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-5969
Version: Published version
Publikationstyp: Zeitschriftenaufsatz
Nutzungsrechte: CC BY
Informationen zu den Nutzungsrechten: https://creativecommons.org/licenses/by/4.0/
Zeitschrift: Breast cancer research and treatment
182
Seitenzahl oder Artikelnummer: 389
399
Verlag: Springer Science + Business Media B.V.
Verlagsort: Dordrecht u.a.
Erscheinungsdatum: 2020
ISSN: 1573-7217
URL der Originalveröffentlichung: https://doi.org/10.1007/s10549-020-05711-5
DOI der Originalveröffentlichung: 10.1007/s10549-020-05711-5
Enthalten in den Sammlungen:JGU-Publikationen

Dateien zu dieser Ressource:
  Datei Beschreibung GrößeFormat
Miniaturbild
krajnak_s.-low-dose_metro-20210527011422443.pdf1.19 MBAdobe PDFÖffnen/Anzeigen